Category - News

Markets

HCW assumes coverage of Mesoblast at buy; PT $6.50

H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Mesoblast (NASDAQ:MESO) with a “buy” rating and price target of $6.50. The stock closed at $4.56 on Jan. 30. Australia-based Mesoblast is focused on...

January 31, 2019

Developments

FDA performs pre-approval inspection of IntelGenx plant for RIZAPORT

The FDA has performed a pre-approval inspection of IntelGenx’s (TSXV:IGX; OTCQX:IGXT) Health Canada-certified cGMP manufacturing facility in Montreal in connection with the company’s NDA for RIZAPORT, a VersaFilm oral...

January 30, 2019

Developments

ArcherDX acquires genetic testing firm Baby Genes

Closely-held ArcherDX acquired genetic testing lab, Baby Genes. It will operate as a wholly-owned subsidiary under the name ArcherDX Clinical Services, and continue to market a suite of existing newborn genetic testing...

January 30, 2019

Markets

Leerink cuts scPharma to MP; PT to $5 from $12

Leerink downgraded scPharmaceuticals (NASDAQ:SCPH) to “market perform” from “outperform” and slashed its price target to $5 from $12 after the company inked a deal to use West Pharmaceuticals’ SmartDose on-body drug...

January 30, 2019

Developments

Lutronic Vision initiates preclinical laser trial for dry AMD

Closely-held Lutronic Vision initiated a preclinical trial to determine the optimal setting for its R:GEN laser for the treatment of the dry form of age-related macular degeneration (AMD). At the conclusion of the...

January 30, 2019

Developments

Triphase Accelerator options leukemia compound to Celgene

Closely-held Triphase Accelerator entered a new strategic partnership with Celgene (NASDAQ:CELG) to develop a preclinical therapeutic compound, TRPH-395, for the treatment of leukemia and other blood cancers...

January 29, 2019

Markets

Stifel starts Evolus at buy; PT $27

Stifel launched coverage of Evolus (NASDAQ:EOLS) with a “buy” rating and 12-month price target of $27. The stock closed at $14.99 on Jan. 28. “Evolus’ success hinges on the potential for Jeuveauto serve as an...

January 29, 2019

Markets

Stifel starts Revance Therapeutics at buy; PT $50

Stifel initiated coverage of Revance Therapeutics (NASDAQ:RVNC) with a “buy” rating and $50 target price. The stock closed at $17 on Jan. 28. Revance’s Daxi product represents “one of the first truly novel neurotoxin...

January 29, 2019

Markets

Roth resumes coverage of Anavex Life Sciences at buy; PT $10

Roth Capital Partners analyst Jotin Marango resumed coverage of Anavex Life Sciences (NASDAQ:AVXL) with a “buy” rating and $10 price target. The stock closed at $1.82 on Jan. 25. “We like the breadth and optionality of...

January 28, 2019

Markets

HCW assumes coverage of IsoRay at buy; PT 70 cents

H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of IsoRay (NYSE American:ISR) with a “buy” rating and price target of 70 cents, saying the company is “at an inflection point of sustainable revenue growth...

January 28, 2019

Category - News

Subscribe